Antisense therapies in neurological diseases

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Targeted gene expression regulation enables novel therapeutic strategies for monogenic neurological disorders.
• Molecular diagnostics facilitate personalized medicine by identifying and targeting the genetic basis of diseases.
• Antisense therapies utilize modified nucleotide sequences to specifically interact with pathogenic DNA or RNA.

Purpose of the Study:

• To review current antisense therapies for neurological disorders at various clinical development stages.
• To highlight advances in antisense oligonucleotide and interfering RNA applications for severe neurological conditions.
• To discuss the potential and challenges of expanding antisense therapies to broader patient populations.

Main Methods:

• Review of clinical trial data for antisense therapies in neurological diseases.
• Analysis of preclinical studies for emerging antisense therapeutic approaches.
• Categorization of therapies based on molecular type (antisense oligonucleotides, interfering RNA) and clinical phase.

Main Results:

• Antisense therapies have demonstrated target engagement and clinical efficacy in several rare neurological disorders.
• Advanced therapies are in Phase 3 or market authorization for spinal muscular atrophy, Duchenne muscular dystrophy, and others.
• Earlier clinical phases (Phase 1B) are investigating treatments for Huntington's disease, synucleinopathies, and tauopathies.

Conclusions:

• Antisense therapies represent significant progress for previously untreatable neurological diseases.
• Expanding success from rare diseases to more common disorders presents a key challenge.
• Further research is needed to address preclinical toxicities and optimize delivery for wider application.